Ion Beam Applications SA (IBAB.BR) stock: key figures, P/E, revenue and dividend
Health Care · Belgium · ISIN BE0003766806
Ion Beam Applications SA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 498.00 m EUR | 620.00 m EUR |
| Gross profit | 166.00 m EUR | 199.00 m EUR |
| Operating income | 28.10 m EUR | 34.73 m EUR |
| EBIT | 17.00 m EUR | 27.00 m EUR |
| Net income | 9.00 m EUR | 12.72 m EUR |
| Diluted EPS – continuing operations | 0.31 EUR | 0.43 EUR |
Full history since 1997, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Ion Beam Applications SA
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compact proton therapy system transforming cancer treatment; Proteus PLUS, a proton therapy solution for cancer centers; and dosimetry solutions that includes radiation therapy; medical imaging; and QUASAR that offers a portfolio of sophisticated phantoms supporting MR guided radiation therapy, motion management, surface guided radiation therapy, geometric distortion analysis, and machine targeting solutions. It also offers radio pharma solutions, including radioisotopes, cyclotrons, and radiochemistry, as well as other integrated and industrial solutions, and services. In addition, the company is involved in construction of proton therapy, and other accelerators equipment and installation services; and operation and maintenance services, as well as sales a license for intellectual property. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
More stocks
- SIERRA BANCORP (BSRR)
- INSTEEL INDUSTRIES INC (IIIN)
- GRAY MEDIA, INC (GTN)
- Zhejiang Jindun Fans Co Ltd (300411.SZ)
- Brightstar Resources Ltd (BTR.AX)
- Tibet Weixinkang Medicine Co Ltd (603676.SS)
- SBC Medical Group Holdings Inc (SBC)
- IDI SCA (IDIP.PA)
- Eastern Communications Co Ltd B (900941.SS)
- AB SA (ABE.WA)
- Terra Drone Corp (278A.T)
- Stendorren Fastigheter AB (STEF B.ST)
Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.